1.16
price down icon1.69%   -0.02
after-market アフターアワーズ: 1.19 0.03 +2.59%
loading
前日終値:
$1.18
開ける:
$1.19
24時間の取引高:
3.79M
Relative Volume:
0.71
時価総額:
$371.80M
収益:
$95,000
当期純損益:
$-327.27M
株価収益率:
-0.5472
EPS:
-2.12
ネットキャッシュフロー:
$-239.25M
1週間 パフォーマンス:
-31.76%
1か月 パフォーマンス:
-18.31%
6か月 パフォーマンス:
-62.34%
1年 パフォーマンス:
-59.44%
1日の値動き範囲:
Value
$1.15
$1.28
1週間の範囲:
Value
$1.09
$1.76
52週間の値動き範囲:
Value
$1.09
$3.78

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name
名前
Allogene Therapeutics Inc
Name
セクター
Healthcare (1153)
Name
電話
(650) 457-2700
Name
住所
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
職員
361
Name
Twitter
@AllogeneTx
Name
次回の収益日
2025-05-02
Name
最新のSEC提出書
Name
ALLO's Discussions on Twitter

ALLO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ALLO
Allogene Therapeutics Inc
1.16 371.80M 95,000 -327.27M -239.25M -2.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
424.99 128.84B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
527.78 65.38B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
549.65 39.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.15 33.82B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
231.99 27.60B 3.81B -644.79M -669.77M -6.24

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-14 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2024-08-08 再開されました Oppenheimer Outperform
2024-05-31 開始されました Piper Sandler Overweight
2024-01-05 ダウングレード Guggenheim Buy → Neutral
2024-01-05 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2023-12-08 開始されました Citigroup Buy
2023-06-26 再開されました Oppenheimer Outperform
2023-03-21 開始されました Bernstein Mkt Perform
2023-01-24 アップグレード JP Morgan Neutral → Overweight
2023-01-06 アップグレード Robert W. Baird Neutral → Outperform
2022-12-12 ダウングレード BofA Securities Buy → Underperform
2022-08-10 ダウングレード Raymond James Outperform → Mkt Perform
2022-07-15 アップグレード Goldman Neutral → Buy
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-28 繰り返されました B. Riley Securities Buy
2021-10-20 開始されました Cowen Outperform
2021-10-08 ダウングレード Goldman Buy → Neutral
2021-10-08 ダウングレード Stifel Buy → Hold
2021-09-23 アップグレード Raymond James Mkt Perform → Outperform
2021-06-21 再開されました Jefferies Buy
2021-05-20 アップグレード Truist Hold → Buy
2021-05-14 開始されました B. Riley Securities Buy
2021-01-26 アップグレード Stifel Hold → Buy
2020-12-10 再開されました H.C. Wainwright Buy
2020-11-24 開始されました BofA Securities Buy
2020-10-23 開始されました RBC Capital Mkts Outperform
2020-06-01 ダウングレード Raymond James Outperform → Mkt Perform
2020-05-29 繰り返されました H.C. Wainwright Buy
2020-05-19 アップグレード ROTH Capital Neutral → Buy
2020-05-15 アップグレード Guggenheim Neutral → Buy
2020-05-14 繰り返されました H.C. Wainwright Buy
2020-05-14 ダウングレード SunTrust Buy → Hold
2020-04-13 開始されました SunTrust Buy
2020-03-13 開始されました H.C. Wainwright Buy
2020-03-05 開始されました Stifel Hold
2020-02-24 開始されました Berenberg Hold
2019-12-18 開始されました JMP Securities Mkt Outperform
2019-11-04 開始されました Canaccord Genuity Buy
2019-08-09 開始されました BTIG Research Buy
2019-06-05 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Neutral
2019-05-23 開始されました Stifel Hold
2019-03-29 開始されました Piper Jaffray Overweight
すべてを表示

Allogene Therapeutics Inc (ALLO) 最新ニュース

pulisher
May 09, 2025

Is Allogene Therapeutics, Inc. (ALLO) the Low Risk High Reward Stock Set to Triple by 2030? - Yahoo Finance

May 09, 2025
pulisher
May 07, 2025

Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) latest 17% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st

May 07, 2025
pulisher
May 06, 2025

Allogene Therapeutics to Report First Quarter 2025 Financial Res - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update - The Manila Times

May 06, 2025
pulisher
Apr 25, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst institutional investors who own 59% - Yahoo Finance

Apr 25, 2025
pulisher
Apr 23, 2025

Allogene Therapeutics (ALLO) to Present New Findings on ALLO-316 and ALPHA3 Trials | ALLO Stock News - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Allogene Therapeutics to Present Updated ALLO-316 Clinical Resul - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Allogene Therapeutics to Present Updated Data on ALLO-316 and ALPHA3 Trials at 2025 ASCO Annual Meeting - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

First Allogeneic CAR T Shows Promise in Solid Tumors: Latest Clinical Data from Dual Cancer Trials at ASCO - Stock Titan

Apr 23, 2025
pulisher
Apr 10, 2025

Allogene received FDA Fast-track statuses for its dual CAR-Therapy - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

Allogene stock hits 52-week low at $1.29 amid sharp annual decline - Investing.com Australia

Apr 10, 2025
pulisher
Apr 09, 2025

Allogene stock hits 52-week low at $1.29 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 08, 2025

FDA Grants Three Fast Track Tags To Allogene's Autoimmune Disease Drug - Barchart.com

Apr 08, 2025
pulisher
Apr 07, 2025

FDA grants fast track status to Allogene’s autoimmune therapy By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

Allogene Therapeutics’ ALLO-329 Snags FDA Fast Track Designations for 3 Rheumatology Indications - CGTLive®

Apr 07, 2025
pulisher
Apr 07, 2025

Allogene's ALLO-329 Granted Three FDA Fast Track Designations - Nasdaq

Apr 07, 2025
pulisher
Apr 07, 2025

Allogene Gets FDA Fast Track Designations for ALLO-329 in Autoimmune Diseases - marketscreener.com

Apr 07, 2025
pulisher
Apr 07, 2025

Allogene Granted Three U.S. FDA Fast Track Designations (Ftd) For Allo-329 - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma - The Manila Times

Apr 07, 2025
pulisher
Apr 07, 2025

FDA grants fast track status to Allogene’s autoimmune therapy - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

Groundbreaking Triple FDA Fast Track: Allogene's New CAR T Targets Multiple Autoimmune Diseases - Stock Titan

Apr 07, 2025
pulisher
Apr 01, 2025

Allogene stock plunges to 52-week low of $1.32 amid steep annual decline - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Allogene stock plunges to 52-week low of $1.32 amid steep annual decline By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Allogene Therapeutics CEO sells $91,469 in stock By Investing.com - Investing.com India

Mar 19, 2025
pulisher
Mar 18, 2025

Allogene Therapeutics CEO sells $91,469 in stock - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Allogene Therapeutics Executives Sell Shares for Tax Obligations - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Renal Cancer Clinical Pipeline | 75+ Companies, Including - openPR.com

Mar 18, 2025
pulisher
Mar 17, 2025

7th Annual Allogeneic Cell Therapies Summit - pharmaphorum

Mar 17, 2025
pulisher
Mar 17, 2025

Allogene Therapeutics' SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Allogene Therapeutics’ SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

Allogeneic T Cell Therapies Market Set For 9.8% Growth, Reaching $1.9 Billion By 2029 - WhaTech

Mar 17, 2025
pulisher
Mar 16, 2025

Allogene upgraded at Citizens after Q4 update - MSN

Mar 16, 2025
pulisher
Mar 15, 2025

Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 15, 2025
pulisher
Mar 15, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 15, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... By GuruFocus - Investing.com Canada

Mar 14, 2025
pulisher
Mar 14, 2025

Citizens Capital Markets Upgrades Allogene Therapeutics (ALLO) - Nasdaq

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... - Yahoo

Mar 14, 2025

Allogene Therapeutics Inc (ALLO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$65.08
price down icon 0.84%
$19.36
price down icon 0.31%
$33.15
price up icon 0.15%
$23.96
price down icon 2.80%
$92.77
price down icon 2.12%
biotechnology ONC
$231.99
price down icon 1.67%
大文字化:     |  ボリューム (24 時間):